Preparation and Biological Evaluation of <sup>64</sup>Cu-CB-TE2A-sst<sub>2</sub>-ANT, a Somatostatin Antagonist for PET Imaging of Somatostatin Receptor–Positive Tumors

Thaddeus J. Wadas, Martin Eiblmaier, Alexander Zheleznyak, Christopher D. Sherman, Riccardo Ferdani, Kexian Liang, Samuel Achilefu, Carolyn J. Anderson

Journal of Nuclear Medicine · 2008 · 74 citations · 26 references

DOIFull text

Open access

Abstract

The PET radiopharmaceutical 64Cu-CB-TE2A-sst2-ANT is an attractive agent, worthy of future study as a PET radiopharmaceutical for the imaging of somatostatin receptor-positive tumors.

References

26